Serum sST2 served as a predictive biomarker in patients at risk of HF and in individuals with established chronic HF [123], but the prognostic value of the biomarker was diminished after adjusting for the clinical status including comorbidity presence (abdominal obesity, diabetes mellitus, and obstructive pulmonary disease) and NT-proBNP [124–126]. This evidence concerns the gene NPPB and hydrops fetalis.